Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.

已完结 10 由 Aixuexi 发布于 2026/9/30 11:57:17

DOI:10.1016/s0140-6736(26)00602-1
作者：Nicoletta Colombo,Emese Zsiros,Gabriella Parma,Eliana Rulli,Alexandra Sebastianelli,Mariusz Bidzinski,Carlos Gallardo,Emad Matanes,Kosei Hasegawa,Fatih Kose,Manuel Magallanes-Maciel,Rebecca A Herberts
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BACKGROUND Epithelial ovarian cancer frequently recurs and becomes resistant to platinum chemotherapy. We investigated whether adding pembrolizumab to weekly paclitaxel, with or without bev

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierLigand engineering enhances Co-MOF/GF anode electrochemical degradation of atrazine.